Status
Completed
Phase
Phase 2 / Phase 3
Enrollment
25
Locations
1
Results
Posted
Publications
0
Study summary
Lipodystrophies represent a therapeutic challenge with regards to insulin resistance, hypertriglyceridemia and fatty liver which often is coupled with significant adipose tissue loss. The purpose of the study is to examine the safety and efficacy of Leptin on subjects with lipodystrophy.
The mechanism by which leptin improves glucose and lipid control is not clear. We will examine the possible mechanisms of leptin action by studying the effects of leptin administration on food intake, insulin resistance, insulin secretory response, hepatic and intramuscular triglyceride stores in a large sample of patients with lipodystrophy. Hypothesis: Leptin replacement in patients with generalized and partial lipodystrophy and hypoleptinemia will be safe and efficacious in improving the metabolic abnormalities associated with insulin resistance.
Interventions
DRUG
Leptin injected subcutaneously twice a day, to be administered at 100% of the estimated replacement dose during the first month, which is a dosage of 0.03mg/kg for female children, 0.04mg/kg for adult females, and0.02 mg/kg for all males, and then at 200% subsequently, or placebo.
DRUG
Sugar pill
Timeline
First posted
May 11, 2009
Study start
Apr 2006
Primary completion
Nov 2014
Study completion
Nov 2014
Results posted
Mar 5, 2019
Registry updated
Mar 27, 2024
Outcomes
Fasting Serum Triglycerides
Time frame · 4 months
HbA1c
Time frame · 4 months
Fasting Serum Glucose
Time frame · 4 months
Body Weight
Time frame · 4 months
Eligibility
Inclusion Criteria: * age \> 6 years * Partial and generalized lipodystrophy * Serum leptin levels less than the 7th percentile of normal values reported by the 3rd National Health and Nutrition Examination survey (less than 7.0 ng/mL in females and less than 3/0 ng/mL in males) * Presence of at least one of the following metabolic abnormalities: 1. Type 2 Diabetes Mellitus 2. Fasting serum insulin \>20 uU/mL 3. Fasting serum triglycerides \> 300 mg/dL 4. Previous participation in leptin trial (Amgen 991265, GCRC 660) - for Part B of the Study. Exclusion Criteria: * Known liver disease due to causes other than non-alcoholic steatohepatitis. * Hematocrit of less than 30%. * Current alcohol or substance abuse. * Use of anorexigenic drugs, anabolic steroids, GH and thiazolidinediones * Active tuberculosis * Psychiatric disorder impeding competence or compliance * Malignancies * HIV infection * Subjects who have a known hypersensitivity to E. Coli derived proteins * Other condition, which in the opinion of the clinical investigators would impede completion of the study.
Study locations
United States. Showing up to 24 locations stored in the fast local snapshot.
UT Southwestern Medical Center
Dallas, Texas, United States
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
Gabriella Milos · Anorexia Nervosa
Phase 2
Recruiting
50
2026-07
Regeneron · Generalized Lipodystrophy
Phase 3
Completed
9
2026-07
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Diabetes · Lipodystrophy
Phase 2
Active, not recruiting
29
2026-07
Amryt Pharma · Generalized Lipodystrophy
Phase 3
Terminated
1
2026-07
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Lipodystrophy · Diabetes
Phase 3
Active, not recruiting
24
2026-07
Chiesi Farmaceutici S.p.A. · Generalised Lipodystrophy · Partial Lipodystrophy
Not applicable
Recruiting
100
2026-07
Chiesi Farmaceutici S.p.A. · Familial Partial Lipodystrophy
Phase 3
Recruiting
24
2026-07
Chiesi Farmaceutici S.p.A. · Partial Lipodystrophy
Phase 3
Active, not recruiting
69
2026-06
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.